Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyAli Reza Golshayan, Saby George, Daniel Y Heng, et al.Journal for Immunotherapy of Cancer|October 19, 2018
Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumabHaris Zahoor, Pedro C Barata, Xuefei Jia, et al.Clinical Genitourinary Cancer|March 3, 2019
Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint InhibitorsMoshe C Ornstein, Cassandra Calabrese, Laura S Wood, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work GroupAlexander I Spira, Mark D Stewart, Suzanne Jones, et al.Clinical Genitourinary Cancer|September 3, 2018
Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell CarcinomaPedro C Barata, Prateek Mendiratta, Rupesh Kotecha, et al.Cancer|March 1, 2014
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapyJorge A Garcia, Gary R Hudes, Toni K Choueiri, et al.The Lancet. Oncology|August 21, 2019
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 studyMoshe C Ornstein, Sumanta K Pal, Laura S Wood, et al.The Journal of Urology|March 28, 2015
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal ParenchymaBrian I Rini, Elizabeth R Plimack, Toshio Takagi, et al.Journal for Immunotherapy of Cancer|December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)Brian I Rini, Dena Battle, Robert A Figlin, et al.Journal for Immunotherapy of Cancer|November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinomaBrian I Rini, David F McDermott, Hans Hammers, et al.Pageof 4